Mexican tomato exporters are conducting unfair trade practices and dumping tomatoes into the U.S. market, despite the 2019 Tomato Suspension Agreement. This is forcing American tomato farmers out of business and destroying the domestic tomato industry. U.S....
U.S. Senator Marco Rubio’s (R-FL) office will host in-person and virtual Mobile Office Hours next week to assist constituents with federal casework issues in their respective local communities. These office hours offer constituents who do not live close to one of...
El senador estadounidense Marco Rubio (R-FL) habló con Nio Encendio de Maxima 92.5 de Tampa Bay, sobre cómo la inflación ha impactado a las familias, sobre las olas de migración ilegal, sobre el juicio político de Biden vs. el de Trump, sobre el canje de prisioneros...
This year alone, U.S. Customs and Border Protection (CBP) has encountered an estimated 40,000 Chinese nationals along the U.S. northern and southern border. The Biden Administration has left the border wide open, allowing potential spies from the Chinese Communist...
Gotion, Inc., a Chinese company and U.S. subsidiary of Guoxuan High-Tech, announced a lithium battery plant in Illinois that is expected to open next year. This CCP-tied battery company is expected to benefit from green-energy tax breaks under the Democrats’ Inflation...
U.S. Senator Marco Rubio (R-FL) joined National Public Radio’s All Things Considered to discuss his plan to expand the child tax credit for working families. See below for the full transcript and listen to the edited interview here. On the connection between the child...
Washington, D.C. — U.S. Senators Marco Rubio (R-FL), Rick Scott (R-FL), Josh Hawley (R-MO), Ron Johnson (R-WI), Mike Braun (R-IN), Kevin Cramer (R-ND), Cindy Hyde-Smith (R-MS) and Dan Sullivan (R-AK) sent a letter to the president and CEO of Pharmaceutical Research and Manufacturers of America (PhRMA) asking that they provide solutions to address the rising cost of prescription drugs.
The full text of the letter is below.
Dear Mr. Ubl,
We hear it every day in our states. Drug prices are too high. Patients are paying more and more every year for life-saving drugs, and some are forced to go without those treatments because they simply cannot afford them.
Soaring drug prices are a serious problem and a problem Washington should have addressed long ago. We cannot understand why Americans pay two to six times more than the rest of the world for brand name prescription drugs or why the U.S. comprised 42% of global pharmaceutical revenues based on 2016 data. American consumers should not be subsidizing European countries so they can keep prices low for their consumers. The system needs to change.
Transparency in health care costs is key to giving patients flexibility and control over their health care decisions. American consumers should always come first, and it is time for U.S. companies to be more transparent and bring down the prices of prescription drugs for Americans relative to Canada, Europe and other developed nations.
We write today to ask, as the trade association representing the pharmaceutical industry, what solutions does your association have that would increase transparency and directly lower the list price of drugs for consumers? What specific plans do you have to address price disparities in the international market? And are you willing to work with us to find real solutions to help the American people?
In Washington, there is often too much finger pointing and not enough problem solving. We do not accept that. We are working to find solutions that directly help patients get the health care they deserve. Thank you in advance for your response. We look forward to your cooperation as we work together to lower the cost of prescription drugs.
Sincerely,